Calcium Channel Blockade in Primary Aldosteronism

Completed · Phase 2

Conditions studied: Primary Aldosteronism, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)

In brief

This pilot study explore whether the calcium channel blocker amlodipine can lower aldosterone levels in people with primary aldosteronism.

Key facts

Study ID

NCT04179019

Run by

Brigham and Women's Hospital

People needed

15

Starts

2020-09-01

Expected to finish

2023-12-30

Last updated by the study team

2025-04-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of primary aldosteronism
• Idiopathic bilateral hyperaldosteronism subtype based on adrenal venous sampling
• Primary aldosteronism treated with medical therapy (not surgery)
• Plasma renin activity <1.0 ng/mL/h

You may not qualify if…

• large or discrete adrenal adenoma on cross-sectional imaging
• inability to stop calcium channel blocker and transition to alternative medication
• inability to stop mineralocorticoid receptor antagonist and transition to alternative medication if plasma renin activity > 1.0 ng/mL/h
• Anemia
• leukopenia
• thrombocytopenia
• pregnant
• breastfeeding

Where it is running

• Anand Vaidya — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.